Skip to main content
SpringerLink
Log in

Pioglitazone Improves Diabetic Dyslipidaemia in Patients with Type 2 Diabetes Mellitus with or without Lipid-Lowering Therapy

  • Short Communication
  • Published:
Clinical Drug Investigation Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Haffner SM, Howard G, Mayer E, et al. Insulin sensitivity and acute insulin response in African Americans, non-Hispanic whites and Hispanic subjects with NIDDM: the Insulin Resistance Atherosclerosis Study. Diabetes 1997; 46: 63–9

    Article  PubMed  CAS  Google Scholar 

  2. Pyörälö K, Laakso M, Uusitupa M. Diabetes and atherosclerosis: an epidemiological view. Diabetes Metab Rev 1987; 3: 463–524

    Article  Google Scholar 

  3. Derosa G, Cicero AF, Gaddi A, et al. Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: a twelve-month, multicenter, double-blind, randomized, controlled, parallel-group trial. Clin Ther 2004; 26: 744–54

    Article  PubMed  CAS  Google Scholar 

  4. Herz M, Johns D, Reviriego J, et al. A randomized, double-blind, placebo-controlled, clinical trial of the effects of pioglitazone on glycemic control and dyslipidemia in oral antihyperglycemic medication-naive patients with type 2 diabetes mellitus. Clin Ther 2003; 25: 1074–95

    Article  PubMed  CAS  Google Scholar 

  5. Assmann G, Cullen P, Schulte H. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Munster (PROCAM) study. Circulation 2002; 105: 310–5

    Article  PubMed  Google Scholar 

  6. Rosenblatt S, Miskin B, Glazer NB, et al. The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus. Coron Artery Dis 2001; 12: 413–23

    Article  PubMed  CAS  Google Scholar 

  7. Buse JB, Tan MH, Prince MJ, et al. The effects of oral antihyperglycaemic medications on serum lipid profiles in patients with type 2 diabetes. Diabetes Obes Metab 2004; 6: 133–56

    Article  PubMed  CAS  Google Scholar 

  8. Krauss RM. Lipids and lipoproteins in patients with type 2 diabetes. Diabetes Care 2004; 27: 1496–504

    Article  PubMed  CAS  Google Scholar 

  9. Aronoff S, Rosenblatt S, Braithwaite S, et al. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes mellitus: a six-month, randomized, placebo-controlled dose-response study. Diabetes Care 2000; 23: 1605–11

    Article  PubMed  CAS  Google Scholar 

  10. Kipnes MS, Krosnick A, Rendell MS, et al. Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study. Am J Med 2001; 111: 10–7

    Article  PubMed  CAS  Google Scholar 

  11. Einhorn D, Rendell M, Rosenzweig J, et al. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. Clin Ther 2000; 22: 1395–402

    Article  PubMed  CAS  Google Scholar 

  12. Hanefeld M, Brunetti P, Schernthaner GH, et al. One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes. Diabetes Care 2004; 27: 141–7

    Article  PubMed  CAS  Google Scholar 

  13. Rosenstock J, Einhorn D, Hershon K, et al. Efficacy and safety of pioglitazone in type 2 diabetes: a randomised, placebo-controlled study in patients receiving stable insulin therapy. Int J Clin Pract 2002; 56(4): 251–7

    PubMed  CAS  Google Scholar 

  14. Tan MH, Johns D, Glazer NB, et al. Pioglitazone reduces atherogenic index of plasma, an indirect indicator of LDL particle size [abstract]. Diabetes 2001; 50Suppl. 1: A133

    Google Scholar 

  15. Winkler K, Konrad T, Füllert S, et al. Pioglitazone reduces atherogenic dense LDL particles in non-diabetic patients with arterial hypertension: a double-blind, placebo-controlled study. Diabetes Care 2003; 26: 2588–94

    Article  PubMed  CAS  Google Scholar 

  16. Diamant M, Heine RJ. Thiazolidinediones in type 2 diabetes mellitus: current clinical evidence. Drugs 2003; 63(13): 1373–405

    Article  PubMed  CAS  Google Scholar 

  17. Jones NP, Mather RA, Sautter M. Rosiglitazone treatment does not impair the triglyceride-lowering activity of fibrates in patients with type 2 diabetes mellitus. Diabetes 2000; 40: 1507–PO

    Google Scholar 

  18. Suraamornkul S, Glass L, Kashyap R, et al. Effects of pioglitazone versus fenofibrate treatment on glucose and fat metabolism in patients with type 2 diabetes. 18th IDF Congress, August 2003, Paris/France: P-833

  19. Prueksaritanont T, Vega JM, Zhao J, et al. Interactions between simvastatin and troglitazone or pioglitazone in healthy subjects. J Clin Pharmacol 2001; 41: 573–81

    Article  PubMed  CAS  Google Scholar 

  20. Freed MI, Ratner R, Marcovina SM, et al. Effects of rosiglitazone alone and in combination with atorvastatin on the metabolic abnormalities in type 2 diabetes mellitus. Am J Cardiol 2002; 90: 947–52

    Article  PubMed  CAS  Google Scholar 

  21. Derosa G, Cicero AFG, Ragonesi PD, et al. Lipid and lipoprotein effects of rosiglitazone alone and in association with simvastatin in patients with metabolic syndrome. Diabetes 2004; 53(2): 1982–PO

    Google Scholar 

  22. Tan SA, Tan LG. Pravastatin affects Th-1 and rosiglitazone Th-2 cytokines, and the synergistic effects of combined pravastatin and rosiglitazone on attenuating inflammatory cytokines and C-reactive protein in diabetic patients with hyperlipidemia and coronary artery disease. Diabetes 2004; 53(2): 395–PD

    Google Scholar 

  23. King AB, Armstrong DU. Lipid response to pioglitazone in diabetic patients: clinical observations from a retrospective chart review. Diabetes Technol Ther 2002; 4: 145–51

    Article  PubMed  CAS  Google Scholar 

  24. Krauss RM. Lipids and lipoproteins in patients with type 2 diabetes. Diabetes Care 2004; 27: 1496–504

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

The study was supported by Takeda Pharma GmbH, Germany. The authors have no conflict of interests that are directly relevant to the content of this article.

Author information

Authors and Affiliations

  1. Abteilung Gastroenterologie, Hepatologie und Endokrinologie, Medizinische Hochschule Hannover, Hannover, Germany

    Christof Schöfl

  2. Aachen, Germany

    Georg Luebben

Authors
  1. Christof Schöfl
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Georg Luebben
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Schöfl, C., Luebben, G. Pioglitazone Improves Diabetic Dyslipidaemia in Patients with Type 2 Diabetes Mellitus with or without Lipid-Lowering Therapy. Clin. Drug Investig. 25, 341–345 (2005). https://doi.org/10.2165/00044011-200525050-00007

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00044011-200525050-00007

Keywords

Search

Navigation